Ursodeoxycholic acid for patients with primary biliary cirrhosis: An updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses

American Journal of Gastroenterology

Volumn 102, Issue 8, 2007, Pages 1799-1807

  Gong, Yan ^a   Huang, Zhibi ^b   Christensen, Erik ^c   Gluud, Christian ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID;

ASCITES; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; JAUNDICE; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; PORTAL VEIN BLOOD PRESSURE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN;

BAYES THEOREM; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; URSODEOXYCHOLIC ACID; WEIGHT GAIN;

EID: 34547642138     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01235.x     Document Type: Review

References (57)

1. MacMahon HE, Thannhauser SJ. Xanthomatous biliary cirrhosis (a clinical syndrome). Ann Intern Med 1949 30 : 121.
2. Ahrens EH Jr., Payne MA, Kunkel HG, et al. Primary biliary cirrhosis (classical article). Medicine 1994 73 : 264 80.
3. Kim WR, Lindor KD, Locke GR 3rd., et al. Epidemiology and natural history of primary biliary cirrhosis in a U.S. Community. Gatroenterology 2000 119 : 1631 6.
4. Prince MI, James OFW. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003 7 : 795 819.
5. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005 353 : 1261 73.
6. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996 335 : 1570 80.
7. Jazrawi RP, Caestecker JS, Goggin PM, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: Effect of ursodeoxycholic acid. Gastroenterogy 1994 106 : 134 42.
8. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994 19 : 1149 56.
9. Parés A, Caballería L, Rodés J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000 32 : 561 6.
10. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis. Lancet 1999 354 : 1053 60.
11. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. The Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD000551. DOI: 10.1002/14651858.CD000551.
12. Papatheodoridis GV, Hadziyannis ES, Deutsch M, et al. Ursodeoxycholic acid for primary biliary cirrhosis: Final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenterol 2002 97 : 2063 70.
13. Combes B, Luketic VA, Peters MG, et al. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 2004 99 : 264 8.
14. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis [see comments]. Gastroenterology 1994 106 : 1284 90.
15. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis (updated protocol). In : The Cochrane Library, Issue 2, 1999. Oxford : Update Software.
16. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. In : The Cochrane Library, Issue 3, 2005. Chichester, UK : John Wiley & Sons, Ltd.
17. Gluud C, Als-Nielsen B, D'Amico G, et al. About The Cochrane Collaboration, The Cochrane Hepato-Biliary Group. Issue 3, 2006. The Cochrane Collaboration. Chichester, UK : John Wiley & Sons, Ltd.
18. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995 273 : 408 12.
19. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998 352 : 609 13.
20. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001 135 : 982 9.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 88.
22. DeMets DL. Methods of combining randomized clinical trials: Strengths and limitations. Stat Med 1987 6 : 341 50.
23. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002 21 : 1539 58.
24. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994 50 : 1088 101.
25. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple graphical test. BMJ 1997 315 : 629 34.
26. Gamble C, Hollis S. Uncertainty method improved on best/worst case analysis in a binary meta-analysis. J Clin Epidemiol 2005 58 : 579 88.
27. Whitehead A. A Bayesian approach to meta-analysis. Chichester, UK : John Wiley & Sons, Ltd, 2002 259 84.
28. Sharp SJ, Thompson SG. Analysing the relationship between treatment effect and underlying risk in meta-analysis: Comparison and development of approaches. Stat Med 2000 19 : 3251 74.
29. Goddard CJR, Hunt L, Smith A, et al. A trial of ursodeoxycholic acid (UDCA) and colchine in primary biliary cirrhosis (PBC) [AASLD abstract]. Hepatology 1994 20 : 151A.
30. De la Mora G, Bobadilla J, Romero P, et al. Does treatment with ursodeoxycholic acid (UDCA) really diminish cholesterol serum levels in primary biliary cirrhosis (PBC)? [Iasl abstract]. Hepatology 1994 19 : 57I.
31. Eriksson LS, Olsson R, Glauman H, et al. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scand J Gastroenterol 1997 32 : 179 86.
32. Battezzati PM, Podda M, Bianchi FB, et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J Hepatol 1993 17 : 332 8.
33. Poupon RE, Balkau B, Eschwège E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991 324 : 1548 54.
34. Combes B, Luketic VA, Peters MG, et al. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 2004 99 : 264 8.
35. Oka H, Toda G, Ikeda Y, et al. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn 1990 25 : 774 80.
36. Zukowski TH, Jorgensen RA, Dickson ER, et al. Autoimmune conditions associated with primary biliary cirrhosis: Response to ursodeoxycholic acid therapy. Am J Gastroenterol 1998 93 : 958 61.
37. Turner IB, Myszor M, Mitchison HC, et al. A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 1994 9 : 162 8.
38. Jorgensen R, Angulo P, Dickson ER, et al. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Am J Gastroenterol 2002 97 : 2647 50.
39. Leuschner U, Manns MP, Eisebitt R. Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: Effects on progression and prognosis. Z Gastroenterol 2005 43 : 1051 9.
40. Ioannidis JPA, Lau J. Evolution of treatment effects over time: Empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci U S A 2001 98 : 831 6.
41. Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years. Gastroenterology 2002 123 : 1044 51.
42. Simko V, Michael S, Prego V. Ursodeoxycholic therapy in chronic liver disease: A meta-analysis in primary biliary cirrhosis and in chronic hepatitis. Am J Gastroenterol 1994 89 : 392 8.
43. Poupon RE, Lindor KD, Cauch DK, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997 113 : 884 90.
44. Poupon RE. Ursodeoxycholic acid for primary biliary cirrhosis: Lessons from the past - issues for the future. J Hepatol 2000 32 : 685 8.
45. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis: Lesson for the future? J Hepatol 2001 34 : 787 8.
46. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003 362 : 53 61.
47. Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005 28 : 135 45.
48. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006 130 : 715 20.
49. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. JAMA 1991 266 : 93 8.
50. Oxman AD, Gayatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992 116 : 78 84.
51. Assmann SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000 355 : 1064 9.
52. Pasha T, Heathcote J, Gabriel S, et al. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999 29 : 21 6.
53. Gluud C, Brok J, Gong Y, et al. Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007 46 : 734 42.
54. Kürstein P, Kjellberg J, Herbild L, et al. Fra forskning til praksis [From research into practice] DSI Institut for Sundhedsvæsen [DSI Institute for Health Services Research] and The Cochrane Hepato-Biliary Group. DSI Rapport 2005 : 1 142.
55. Kürstein P, Gluud LL, Willemann M, et al. Agreement between reported use of interventions for liver diseases and research evidence in Cochrane systematic reviews. J Hepatol 2005 43 : 984 9.
56. Baker SG, Kramer BS. A perfect correlate does not a surrogate make. BMC Med Res Methodol 2003 3 : 16.
57. Mayo MJ. Patients and patience: The pitfalls of primary biliary cirrhosis trials. Nat Clin Prac Gastroenterol Hepatol 2005 2 : 552 3.